Search

Your search keyword '"Haslbauer, Ferdinand"' showing total 24 results
Start Over Author "Haslbauer, Ferdinand"
24 results on '"Haslbauer, Ferdinand"'

2. Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2− advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT

Author

Steger, Guenther G., Egle, Daniel, Bartsch, Rupert, Pfeiler, Georg, Petru, Edgar, Greil, Richard, Helfgott, Ruth, Marth, Christian, Öhler, Leopold, Hubalek, Michael, Lang, Alois, Tinchon, Christoph, Haslbauer, Ferdinand, Redl, Andreas, Hock, Karin, Hennebelle, Mathias, Mraz, Bernhard, and Gnant, Michael

Published
2020
Full Text
View/download PDF

4. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Gnant, Michael, Pfeiler, Georg, Steger, Günther G, Egle, Daniel, Greil, Richard, Fitzal, Florian, Wette, Viktor, Balic, Marija, Haslbauer, Ferdinand, Melbinger-Zeinitzer, Elisabeth, Bjelic-Radisic, Vesna, Jakesz, Raimund, Marth, Christian, Sevelda, Paul, Mlineritsch, Brigitte, Exner, Ruth, Fesl, Christian, Frantal, Sophie, and Singer, Christian F

Published
2019
Full Text
View/download PDF

5. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial

Author

Gnant, Michael, Pfeiler, Georg, Dubsky, Peter C, Hubalek, Michael, Greil, Richard, Jakesz, Raimund, Wette, Viktor, Balic, Marija, Haslbauer, Ferdinand, Melbinger, Elisabeth, Bjelic-Radisic, Vesna, Artner-Matuschek, Silvia, Fitzal, Florian, Marth, Christian, Sevelda, Paul, Mlineritsch, Brigitte, Steger, Günther G, Manfreda, Diether, Exner, Ruth, Egle, Daniel, Bergh, Jonas, Kainberger, Franz, Talbot, Susan, Warner, Douglas, Fesl, Christian, and Singer, Christian F

Published
2015
Full Text
View/download PDF

7. Long-Term Outcomes of Adjuvant Denosumab in Breast Cancer

Author

Gnant, Michael, primary, Frantal, Sophie, additional, Pfeiler, Georg, additional, Steger, Guenther G., additional, Egle, Daniel, additional, Greil, Richard, additional, Fitzal, Florian, additional, Wette, Viktor, additional, Balic, Marija, additional, Haslbauer, Ferdinand, additional, Melbinger-Zeinitzer, Elisabeth, additional, Bjelic-Radisic, Vesna, additional, Artner-Matuschek, Silvia, additional, Kainberger, Franz, additional, Ritter, Magdalena, additional, Rinnerthaler, Gabriel, additional, Sevelda, Paul, additional, Bergh, Jonas, additional, Kacerovsky-Strobl, Stephanie, additional, Suppan, Christoph, additional, Brunner, Christine, additional, Deutschmann, Christine, additional, Gampenrieder, Simon P., additional, Fohler, Hannes, additional, Jakesz, Raimund, additional, Fesl, Christian, additional, and Singer, Christian, additional

Published
2022
Full Text
View/download PDF

9. Long-term outcomes of adjuvant denosumab in breast cancer: Fracture reduction and survival results from 3,425 patients in the randomised, double-blind, placebo-controlled ABCSG-18 trial.

Author

Gnant, Michael, primary, Frantal, Sophie, additional, Pfeiler, Georg, additional, Steger, Guenther G., additional, Egle, Daniel, additional, Greil, Richard, additional, Fitzal, Florian, additional, Wette, Viktor, additional, Balic, Marija, additional, Haslbauer, Ferdinand, additional, Melbinger-Zeinitzer, Elisabeth, additional, Bjelic-Radisic, Vesna, additional, Brunner, Christine, additional, Artner-Matuschek, Silvia, additional, Rinnerthaler, Gabriel, additional, Wimmer, Kerstin, additional, Bergh, Jonas C. S., additional, Fesl, Christian, additional, and Singer, Christian F., additional

Published
2022
Full Text
View/download PDF

11. Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer

Author

Gnant, Michael, primary, Fitzal, Florian, additional, Rinnerthaler, Gabriel, additional, Steger, Guenther G., additional, Greil-Ressler, Sigrun, additional, Balic, Marija, additional, Heck, Dietmar, additional, Jakesz, Raimund, additional, Thaler, Josef, additional, Egle, Daniel, additional, Manfreda, Diether, additional, Bjelic-Radisic, Vesna, additional, Wieder, Ursula, additional, Singer, Christian F., additional, Melbinger-Zeinitzer, Elisabeth, additional, Haslbauer, Ferdinand, additional, Sevelda, Paul, additional, Trapl, Harald, additional, Wette, Viktor, additional, Wimmer, Kerstin, additional, Gampenrieder, Simon P., additional, Bartsch, Rupert, additional, Kacerovsky-Strobl, Stephanie, additional, Suppan, Christoph, additional, Brunner, Christine, additional, Deutschmann, Christine, additional, Soelkner, Lidija, additional, Fesl, Christian, additional, and Greil, Richard, additional

Published
2021
Full Text
View/download PDF

12. Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients

Author

Fiegl, Michael, Falkner, Florian, Steurer, Michael, Zojer, Niklas, Hopfinger, Georg, Haslbauer, Ferdinand, Winder, Guntram, Voskova, Daniela, Andel, Johannes, Lang, Alois, Brychtova, Yvona, Mayer, Jiri, Greil, Richard, Gastl, Günther, and for The Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia, in cooperation with The Czech Leukemia Study Group for Life, CELL

Published
2011
Full Text
View/download PDF

14. Prospective observational study to evaluate the persistence of treatment with denosumab in patients with bone metastases from solid tumors in routine clinical practice: final analysis

Author

Haslbauer, Ferdinand, primary, Petzer, Andreas, additional, Safanda, Martin, additional, Tomova, Antoaneta, additional, Porubska, Miriam, additional, Bajory, Zoltán, additional, Niepel, Daniela, additional, Jaeger, Christine, additional, Bjorklof, Katja, additional, Kalinin, Dmitry, additional, and Greil, Richard, additional

Published
2019
Full Text
View/download PDF

15. REACHAUT: First-line (1L) ribociclib (RIB) + endocrine therapy (ET) in HR+, HER2- metastatic breast cancer (MBC) in the real-world setting.

Author

Singer, Christian F., primary, Öhler, Leopold, additional, Egle, Daniel, additional, Greil, Richard, additional, Petru, Edgar, additional, Balic, Marija, additional, Marhold, Maximilian, additional, Pfeiler, Georg, additional, Brunner, Christine, additional, Kwasny, Werner, additional, Galid, Arik Armon, additional, Tinchon, Christoph, additional, Eisterer, Wolfgang, additional, Haslbauer, Ferdinand, additional, Hubalek, Michael, additional, Redl, Andreas, additional, Hock, Karin, additional, Hennebelle, Mathias, additional, Mraz, Bernhard, additional, and Steger, Guenther G., additional

Published
2019
Full Text
View/download PDF

16. Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial.

Author

Gnant, Michael, primary, Pfeiler, Georg, additional, Steger, Guenther G., additional, Egle, Daniel, additional, Greil, Richard, additional, Fitzal, Florian, additional, Wette, Viktor, additional, Balic, Marija, additional, Haslbauer, Ferdinand, additional, Melbinger-Zeinitzer, Elisabeth, additional, Bjelic-Radisic, Vesna, additional, Bergh, Jonas C. S., additional, Jakesz, Raimund, additional, Marth, Christian, additional, Sevelda, Paul, additional, Mlineritsch, Brigitte, additional, Exner, Ruth, additional, Fesl, Christian, additional, Frantal, Sophie, additional, and Singer, Christian F., additional

Published
2018
Full Text
View/download PDF

18. P3.02b-101 EGFR T790M Resistance Mutation in NSCLC: Real-Life Data of Austrian Patients Treated with Osimertinib

Author

Hochmair, Maximilian, primary, Holzer, Sophia, additional, Filipits, Martin, additional, Mohn-Staudner, Andrea, additional, Errhalt, Peter, additional, Absenger, Gudrun, additional, Bundalo, Tatjana, additional, Arns, Madeleine, additional, Setinek, Ulrike, additional, Mikes, Romana, additional, Kolb, Rainer, additional, Schumacher, Michael, additional, Zöchbauer-Müller, Sabine, additional, Patocka, Kurt, additional, Haslbauer, Ferdinand, additional, Rudzki, Jakob, additional, and Burghuber, Otto, additional

Published
2017
Full Text
View/download PDF

19. EGFR T790M resistance mutation in NSCLC: Real-life data of patients treated with osimertinib.

Author

Hochmair, Maximilian J., primary, Holzer, Sophia, additional, Filipits, Martin, additional, Mohn-Staudner, Andrea, additional, Arns, Madeleine, additional, Errhalt, Peter, additional, Absenger, Gudrun, additional, Koller-Herzog, Ursula, additional, Setinek, Ulrike, additional, Haslbauer, Ferdinand, additional, Korger, Mark A., additional, Patocka, Kurt, additional, Kolb, Rainer, additional, and Burghuber, Otto, additional

Published
2016
Full Text
View/download PDF

20. Pegfilgrastim Use and Outcomes In Non-Hodgkin-Lymphoma Patients Receiving Chemotherapy In Clinical Practice: Combined Analysis Of The Austrian and Swiss E-Avare Studies

Author

Willenbacher, Wolfgang, primary, Haslbauer, Ferdinand, additional, Neumeister, Peter, additional, Guttmann, Anton, additional, Sperb, Roland, additional, Lohri, Andreas, additional, Saldutto, Biagio, additional, Jaeger, Christine, additional, Bast, Carine, additional, and Renner, Christoph, additional

Published
2013
Full Text
View/download PDF

21. Alemtuzumab Is Effective in Patients with Advanced, Pretreated B-Cell Chronic Lymphocytic Leukemia: A Nationwide Study of Routine Use in Austria.

Author

Fiegl, Michael, primary, Falkner, Andreas, primary, Hopfinger, Georg, primary, Brugger, Stefan, primary, Zabernigg, August, primary, Haslbauer, Ferdinand, primary, Andel, Johannes, primary, Thaler, Josef, primary, Fridrik, Michael, primary, Bauer, Franz, primary, Mian, Michael, primary, Tatzreiter, Georg, primary, Zojer, Niklas, primary, Demirtas, Dita, primary, Postner, Gerhard, primary, Auberger, Jutta, primary, Gastl, Günther, primary, and Greil, Richard, primary

Published
2005
Full Text
View/download PDF

22. Anemia prevalence and treatment practice in patients with non-myeloid tumors receiving chemotherapy.

Author

Merlini, Laura, Cartenì, Giacomo, Iacobelli, Stefano, Stelitano, Caterina, Airoldi, Mario, Balcke, Peter, Keil, Felix, Haslbauer, Ferdinand, Belton, Laura, and Pujol, Beatriz

Subjects
ANEMIA, CANCER chemotherapy, HEMOGLOBINS, ERYTHROCYTES, BLOOD cells
Abstract

Purpose: To describe the prevalence and management of anemia in cancer patients. Methods: This cross-sectional, observational survey was conducted in Italy and Austria. Centers prespecified one day, during a 4-month enrollment window, to report specific data collected during normal clinical practice for patients with non-myeloid tumors attending for chemotherapy (±radiotherapy) treatment. The primary endpoint was the prevalence of anemia as determined using a prespecified algorithm: hemoglobin (Hb) ⩽10 g/dL on/within 3 days prior to visit; ongoing anemia treatment; physician diagnosis of anemia, together with ⩾1 anemia symptom. Results: Between November 18, 2010 and March 18, 2011, data for 1412 patients were collected (Italy n = 1130; Austria n = 282). Most patients (n = 1136; 80%) had solid tumors; 809 (57%) had received ⩽3 chemotherapy cycles. The prevalence of anemia was 32% (95% confidence interval: 29.4%-34.2%); 196 patients (14%) were deemed anemic based on Hb ⩽10 g/dL, 131 (9%) on ongoing anemia treatment, and 121 (9%) on physician diagnosis/anemia symptom. Overall, 1153 patients (82%) had Hb data; mean (standard deviation [SD]) Hb levels were 11.7 (1.7) g/dL. In total, 456 patients (32%) had anemia symptoms: fatigue (n = 392; 28%), depression (n = 122; 9%), and dyspnea (n = 107; 8%) were most common. Fifty-one patients (4%) had had their current chemotherapy cycle delayed due to anemia. On visit day, or ⩽28 days prior, 91 (6%), 188 (13%), and 81 patients (6%) had evidence of whole blood/red blood cell transfusion, erythropoiesis-stimulating agent use, or iron use, respectively. Conclusion: On the prespecified study day, one-third of patients with non-myeloid tumors undergoing chemotherapy were found to be anemic and 13% had evidence of erythropoiesis-stimulating agent use then or in the 28 days prior. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

23. Routine clinical use of alemtuzumab in patients with heavily pretreated B‐cell chronic lymphocytic leukemiaPreliminary data from this study were presented in part at the 47th Annual Meeting of the American Society of Hematology, Atlanta, Georgia, December 10–13, 2005.Additional contributors to this work included the following (Austrian centers): F. X. Schmid (Bregenz); A. Lang (Feldkirch); C. Ludescher, J. Kantner, R. Stauder, J. Büchel, J. Auberger, and M. Steurer (Innsbruck); A. Sahanic (Natters); L. Köck (Lienz); V. Faber and P. Mayer (Salzburg); G. Lobmair (Ried); D. Voskova (Linz); J. Schwarzmeier, M. Shehata, D. Heintel, and U. Jäger (Vienna); G. Jager (Graz); W. Lin (Villach); and H. Weiss (St. Veit).: A nation‐wide retrospective study in Austria

Author

Fiegl, Michael, Falkner, Andreas, Hopfinger, Georg, Brugger, Stefan, Zabernigg, August, Bauer, Franz, Haslbauer, Ferdinand, Demirtas, Dita, Grossschmidt, Peter, Tatzreiter, Georg, Gastl, Günther, and Greil, Richard

Abstract

In previous studies, alemtuzumab demonstrated considerable activity in patients with previously treated B‐cell chronic lymphocytic leukemia (CLL), including fludarabine‐refractory disease. In this retrospective study, the authors evaluated the benefit of alemtuzumab monotherapy in unselected patients with advanced, previously treated CLL who received treatment in the routine clinical setting.Data were collected from 115 consecutive patients who received alemtuzumab therapy at 25 participating centers in Austria. Patients received a median of 3 prior lines of therapy (range, 1–11 prior lines of therapy), and 59% had fludarabine‐refractory disease. Alemtuzumab was administered intravenously or subcutaneously with a planned schedule of 30 mg 3 times per week for up to 12 weeks. Patients received valacyclovir and trimethoprim/sulfamethoxazole for antiinfective prophylaxis.The overall response rate was 23%, with complete responses achieved in 5% of patients. Stable disease (SD) was achieved in 36% of patients. After a median follow‐up of 17.5 months, the median overall survival (OS) was 20.2 months for all patients. A multivariate Cox regression analysis that included pretreatment baseline characteristics, response to therapy, and cumulative dose of alemtuzumab indicated that bulky lymphadenopathy, the administration of ≥3 previous therapies, and lack of response to alemtuzumab remained significant independent risk factors for inferior OS. The median OS had not been reached for responding patients. The median OS was 29.5 months for patients with SD and 10.8 months for patients with progressive disease.The broad use of alemtuzumab in the routine clinical practice setting is feasible and active in unselected patients with pretreated CLL, and the current results confirmed the activity and safety of this agent, as reported in previously published clinical studies. Cancer 2006. © 2006 American Cancer Society.

Published
2006
Full Text
View/download PDF

24. Association between serum IgG concentrations and the incidence of infections in patients with chronic lymphocytic leukemia and secondary immunodeficiency under treatment with Privigen.

Author

Otremba B, Haslbauer F, Reiser M, Weide R, Obermeier M, and Pfründer D

Subjects
Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Agammaglobulinemia epidemiology, Agammaglobulinemia immunology, Agammaglobulinemia blood, Germany epidemiology, Immunologic Deficiency Syndromes epidemiology, Immunologic Deficiency Syndromes immunology, Immunologic Deficiency Syndromes blood, Immunologic Deficiency Syndromes drug therapy, Immunologic Deficiency Syndromes complications, Incidence, Infections epidemiology, Infections immunology, Immunoglobulin G blood, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Leukemia, Lymphocytic, Chronic, B-Cell immunology, Leukemia, Lymphocytic, Chronic, B-Cell epidemiology, Leukemia, Lymphocytic, Chronic, B-Cell blood
Abstract

Objective: To investigate the association between serum immunoglobulin G (IgG) concentrations and the incidence of infections in patients with chronic lymphocytic leukemia (CLL) and secondary immunodeficiency receiving treatment with Privigen., Materials and Methods: Data was analyzed from a non-interventional study conducted in 31 centers in Germany and 1 in Austria. Adult CLL patients with hypogammaglobulinemia and recurrent infections were allowed to enter the study upon signing informed consent, if a prior decision for treatment with Privigen had been made. All infections requiring an antimicrobial treatment were subject to analysis. Patients were stratified according to their mean post-baseline serum IgG trough levels in a group with lower IgG trough levels (≤ 5.0 g/L), and a group with higher IgG trough levels (> 5.0 g/L)., Results: Overall, 89 patients and 840 treatment cycles were analyzed. Up to 11 treatment cycles (average duration 29 days) were documented in each patient. In the group with higher IgG trough levels (> 5.0 g/L, N = 72), significantly fewer infections were observed than in the group with lower IgG trough levels (≤ 5.0 g/L, N = 17), including fewer severe and serious infections. The Privigen dosage was a major determinant of the post-baseline serum IgG levels. Overall tolerability of Privigen was assessed as very good or good in 91% of patients., Conclusion: This analysis confirms the association of serum IgG trough levels with the incidence of infections and highlights the importance of careful monitoring of IgG levels during treatment of secondary immunodeficiencies in CLL patients.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results